EQRX Key Statistics, Chart & Performance
The current stock price of EQRX is 2.34 USD. In the past month the price increased by 5.41%. In the past year, price decreased by -36.24%.
EQRX Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to EQRX. When comparing the yearly performance of all stocks, EQRX is a bad performer in the overall market: 74.99% of all stocks are doing better.
EQRX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to EQRX. EQRX has a great financial health rating, but its profitability evaluates not so good.
EQRX Financial Highlights
Over the last trailing twelve months EQRX reported a non-GAAP Earnings per Share(EPS) of -0.55. The EPS decreased by -62.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.04% | ||
| ROE | -21.05% | ||
| Debt/Equity | 0 |
EQRX Forecast & Estimates
7 analysts have analysed EQRX and the average price target is 2.14 USD. This implies a price decrease of -8.46% is expected in the next year compared to the current price of 2.34.
EQRX Ownership
About EQRX
Company Profile
EQRx, Inc. is a pharmaceutical company, which engages in developing and delivering innovative medicines to patients having chronic conditions. The company is headquartered in Cambridge, Massachusetts and currently employs 362 full-time employees. The company went IPO on 2021-04-09. The firm is engaged in developing medicines for some of the prevalent disease areas, including cancer and immune-inflammatory conditions. The firm brands include EQRx and Remaking Medicine. The firm's pipeline is comprised of approximately 10 programs, including both small molecules and biologics, with five clinical-stage programs, and several disclosed and undisclosed preclinical and drug engineering programs. Its clinical programs include Aumolertinib (EQ143), Lerociclib (EQ132), and Sugemalimab (EQ165). Aumolertinib (EQ143) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Lerociclib (EQ132) is a novel and oral small molecule cyclin-dependent kinase (CDK) 4/6 inhibitor. Sugemalimab (EQ165, also known as CS1001) is an anti-programmed cell death-ligand 1 (PD-L1) monoclonal antibody.
Company Info
EQRX INC
50 Hampshire Street
Cambridge MASSACHUSETTS US
Employees: 362
Phone: 16173152255.0
EQRX INC / EQRX FAQ
What does EQRX do?
EQRx, Inc. is a pharmaceutical company, which engages in developing and delivering innovative medicines to patients having chronic conditions. The company is headquartered in Cambridge, Massachusetts and currently employs 362 full-time employees. The company went IPO on 2021-04-09. The firm is engaged in developing medicines for some of the prevalent disease areas, including cancer and immune-inflammatory conditions. The firm brands include EQRx and Remaking Medicine. The firm's pipeline is comprised of approximately 10 programs, including both small molecules and biologics, with five clinical-stage programs, and several disclosed and undisclosed preclinical and drug engineering programs. Its clinical programs include Aumolertinib (EQ143), Lerociclib (EQ132), and Sugemalimab (EQ165). Aumolertinib (EQ143) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Lerociclib (EQ132) is a novel and oral small molecule cyclin-dependent kinase (CDK) 4/6 inhibitor. Sugemalimab (EQ165, also known as CS1001) is an anti-programmed cell death-ligand 1 (PD-L1) monoclonal antibody.
Can you provide the latest stock price for EQRX INC?
The current stock price of EQRX is 2.34 USD. The price decreased by -2.09% in the last trading session.
Does EQRX stock pay dividends?
EQRX does not pay a dividend.
What is the ChartMill technical and fundamental rating of EQRX stock?
EQRX has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the number of employees for EQRX INC?
EQRX INC (EQRX) currently has 362 employees.
What is EQRX INC worth?
EQRX INC (EQRX) has a market capitalization of 1.26B USD. This makes EQRX a Small Cap stock.